No, methadone will not show up on a standard opiate test. If a drug test cup or lab requisition lists "OPI" or "MOR" as the opiate analyte, that panel is built to catch morphine and codeine, and it will read negative for a patient or employee who has methadone in their system. Catching methadone requires a dedicated MTD analyte on the panel, or a lab-run immunoassay ordered specifically for methadone and its metabolite. This distinction trips up employers, treatment programs, and probation officers constantly, usually right after someone tests clean on a generic panel while a clinician or case manager knows the person is on methadone.
Why the standard opiate antibody misses methadone
Immunoassay opiate screens work by using an antibody that binds to a specific chemical structure. The antibody used in most OPI/MOR test strips and cups was built around morphine's molecular shape, which also picks up codeine and, at high enough concentration, heroin's metabolite. Methadone is a fully synthetic opioid with a different backbone. It does not share enough structural similarity with morphine to trigger that antibody reliably. The NIH's clinical reference on drug testing states plainly that standard immunoassay opiate screens do not reliably detect synthetic opioids such as fentanyl and methadone, and that expanded panels are needed to close that gap.
This is the same reason a suboxone prescription will not flag a standard opiate cup either. Buprenorphine, like methadone, is structurally distant enough from morphine that it needs its own antibody and its own line on the test.
What the MTD panel actually screens for
MTD is the analyte code for methadone on a drug test cup or dip card. When a panel configuration includes MTD, the cup contains a second, separate antibody line built to react to methadone specifically, independent from the OPI/MOR line. A negative OPI result and a positive MTD result on the same cup is not a contradiction. It means the donor has methadone on board and no natural opiates like morphine or codeine.
Labs and treatment programs that need to see methadone results have two paths: order a cup, dip, or panel that already has MTD built in, or send a specimen to a lab and request a methadone-specific immunoassay or confirmation test as an add-on. Either way, methadone has to be asked for by name. It is never assumed as part of a generic "opiates" result.
EDDP: the metabolite that verifies real compliance
In medication-assisted treatment and opioid treatment program settings, clinics often care less about detecting methadone itself and more about detecting EDDP, the primary inactive metabolite the body produces as it metabolizes methadone. The reason is practical: a patient who wants to divert their dose (sell it or give it away) can spike a urine sample with a small amount of the parent drug to fake compliance, but producing EDDP requires the drug to have actually been metabolized by that person's liver. A published GC-MS comparison of methadone and EDDP in patients on methadone substitution treatment found that continuous methadone administration induces methadone metabolism, which increases EDDP levels in urine, and that urine outperforms plasma for this kind of monitoring because it is easier to collect and shows higher detectable levels. That is why compliance-focused testing in MAT clinics is often built around confirming both methadone and EDDP together rather than methadone alone.
Standard opiate panel versus MTD-inclusive panel
| Panel type | What it targets | Methadone result | Typical use case |
|---|---|---|---|
| Standard OPI/MOR (5-panel or similar) | Morphine and codeine, with confirmation testing for 6-AM to identify heroin use | Negative, even in an active methadone patient | General pre-employment or random workplace testing where opioid use disorder treatment is not a factor |
| Expanded opiate panel with MTD | Morphine and codeine plus a dedicated methadone antibody line | Positive when methadone is present, independent of the OPI result | MAT clinics, opioid treatment programs, probation and court-ordered testing where methadone status matters |
| Lab confirmation with EDDP quantification | Methadone plus its EDDP metabolite, quantified by GC-MS or LC-MS/MS | Confirms both use and actual metabolism, harder to fake through spiking | Compliance monitoring and diversion checks inside treatment programs |
How long methadone and EDDP stay detectable
Methadone's elimination half-life is unusually long and variable. The FDA-approved prescribing information for methadone hydrochloride lists a plasma elimination half-life ranging from 8 to 59 hours, with considerable variation between patients based on dose, duration of treatment, liver function, and individual metabolism. Because methadone is lipophilic and accumulates in tissue with repeated dosing, a patient on a stable daily dose clears it far more slowly than someone who took a single dose. That long, variable half-life is why methadone and EDDP tend to stay detectable in urine noticeably longer than short-acting opioids like hydrocodone. Programs that need a precise cutoff for a specific patient should rely on the testing lab's stated detection range for the assay in use rather than a generic number, since dose, duration of use, and metabolism all shift the window.
Why MAT and OTP clinics test for methadone specifically
Opioid treatment programs are not testing for methadone to catch someone doing something wrong. They are confirming that the medication prescribed is the medication actually being taken, and that it is not being diverted. Federal regulation for opioid treatment programs requires random drug testing at a clinically appropriate frequency, with a floor set in regulation. Under 42 CFR 8.12, certified OTPs must use FDA-authorized drug tests and conduct no fewer than eight random drug tests per patient per year, with frequency adjusted based on the patient's stability and response to treatment. A methadone-negative result in a patient who is supposed to be on methadone is itself a clinical red flag worth investigating, just as a positive result for illicit opioids alongside methadone use would be. Our related piece on drug testing in medication-assisted treatment programs covers how clinics structure panels around this kind of monitoring, and the piece on suboxone and buprenorphine panels walks through the parallel situation for buprenorphine-based treatment.
Choosing the right panel
For a general workplace program with no reason to expect methadone use, a standard panel is usually fine. For treatment programs, sober living facilities, probation offices, or any employer that knowingly has staff or clients on medication-assisted treatment, the panel needs an MTD line built in, not bolted on after a negative surprises someone. Multi-panel configurations that include MTD alongside the standard drug classes let a single cup do both jobs at once. Our 12-panel drug test page breaks down which panel configurations include methadone as a standard analyte so clinics and employers can match the cup to the population being tested instead of guessing after the fact.
What a false expectation costs a program
The practical failure point shows up in three settings over and over. An employer runs a standard panel on a new hire who disclosed methadone treatment, the OPI line comes back negative, and the employer wrongly assumes the disclosure was inaccurate or that the person is no longer in treatment. A probation office uses a generic cup that was never configured for methadone, gets a clean opiate read on someone who should be showing methadone as part of a court-monitored MAT condition, and has no record either way. A sober living facility relies on a basic panel and cannot tell the difference between a resident who relapsed on heroin and one who is compliant with a prescribed methadone taper, because the cup was never built to separate those two situations in the first place.
None of these are testing failures in the sense of a bad batch or a faulty cup. They are configuration failures. The panel simply was not asked to look for methadone, so it did not report on methadone. Fixing it means specifying MTD as a required analyte at the point of ordering supplies, not troubleshooting it after a result comes back that does not match what the case file says.
Frequently asked questions
Will a standard 5-panel drug test catch methadone use?
No. A standard 5-panel test screens for marijuana, cocaine, PCP, amphetamines, and an opiate line built around morphine and codeine. Methadone is a separate analyte and will not trigger that opiate line.
What does a positive MTD result mean if the OPI line is negative?
It means the donor has methadone in their system and no detectable morphine or codeine. This is the expected pattern for someone taking prescribed methadone with no other opioid use, and it is not a conflicting or invalid result.
Why do treatment programs test for EDDP instead of just methadone?
EDDP is produced only when the body actually metabolizes methadone. Testing for it helps confirm the patient is taking their dose rather than diverting it and spiking a sample with a small amount of the drug to fake a positive.
Does methadone use affect other parts of a drug test panel?
No. Methadone only affects the methadone-specific analyte line. It does not cause false positives or false negatives on unrelated drug classes like THC, cocaine, or benzodiazepines.
How often are opioid treatment program patients required to be tested?
Federal regulation requires certified opioid treatment programs to conduct random drug testing no fewer than eight times per patient per year, with frequency adjusted based on the patient's clinical stability.
Related reading
This article is general information, not medical or legal advice. Panel selection, cutoff levels, and testing frequency for any clinic, employer, or treatment program should be confirmed with a toxicologist, medical review officer, or the applicable regulatory requirements before a program is put in place.
